Featured Research

from universities, journals, and other organizations

Many mephedrone alternatives just as risky, warn experts

Date:
July 7, 2010
Source:
BMJ-British Medical Journal
Summary:
Since the recent ban on mephedrone, many so-called "legal substitutes" available on the internet are in fact banned cathinones (chemically related to amphetamines) and just as risky, warn experts.

Since the recent ban on mephedrone, many so-called "legal substitutes" available on the internet are in fact banned cathinones (chemically related to amphetamines) and just as risky, warn experts in a letter to this week's British Medical Journal.

One such product is Energy 1 (NRG-1), also advertised as naphyrone (naphthylpyrovalerone, O-2482), write Simon Brandt and colleagues. These products are offered as legal substitutes for the recently criminalised "legal highs," the mephedrone derivatives.

Previous studies exploring the motivation for using these drugs suggested that consumers think that they are more likely to be of higher purity than street drugs, carry a lower risk of physical harm, and not be liable for the criminal sanctions associated with drugs controlled under the Misuse of Drugs Act.

To obtain an initial snapshot of the post-ban situation, they purchased 17 products online from 12 UK based websites over the six weeks after the ban on mephedrone in mid-April 2010. Chemical analysis was carried out by established procedures.

They found that most of the NRG-type products were recently banned cathinones that just carried a new label. This suggests that both consumers and online sellers are, most likely without knowledge, at risk of criminalisation and potential harm, they say.

They conclude: "This has important health and criminal justice consequences that will require carefully thought out responses and further investigation."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Many mephedrone alternatives just as risky, warn experts." ScienceDaily. ScienceDaily, 7 July 2010. <www.sciencedaily.com/releases/2010/07/100706204705.htm>.
BMJ-British Medical Journal. (2010, July 7). Many mephedrone alternatives just as risky, warn experts. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100706204705.htm
BMJ-British Medical Journal. "Many mephedrone alternatives just as risky, warn experts." ScienceDaily. www.sciencedaily.com/releases/2010/07/100706204705.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins